DF
VKTX icon

Dunhill Financial’s Viking Therapeutics VKTX Stock Holding History

Dunhill Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62 Hold
1
– – ﹤0.01% 1481
2026
Q1 		$52 Sell
1
-101
-99% -$3.25K ﹤0.01% 1596
2025
Q4 		$3.58K Buy
+102
New +$3.61K ﹤0.01% 640
2025
Q2 		– Sell
-500
Closed -$12.1K – 1131
2025
Q1 		$12.1K Buy
+500
New +$15.8K 0.01% 373

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dunhill Financial's VKTX Position: Q2 2026 in Review

Dunhill Financial held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 1 share worth $62. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

Dunhill Financial first reported a position in VKTX in Q1 2025 and has held it in 4 quarters since. The position peaked at $12.1K in Q1 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Dunhill Financial held 1 share of Viking Therapeutics worth $62 as of Q2 2026.
  • Dunhill Financial left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1481 holding.
  • Dunhill Financial first reported a position in Viking Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Dunhill Financial's Viking Therapeutics position peaked at $12.1K in Q1 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.